TNGXHealthcare · BiotechnologyThe 12 Wall Street analysts covering Tango Therapeutics, Inc. hold a median 12-month price target of $40 — +68.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 12 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Tango Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (92): The shares have been drifting up relative to others.
Accruals (23): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TNGX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +68.2% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $66 → $68 |
| 12 Aug 2026 | Guggenheim | Maintains | Buy | $32 → $35 |
| 17 July 2026 | Mizuho | Maintains | Outperform | $36 → $40 |
| 17 July 2026 | Mizuho | Maintains | Outperform | — |
| 15 July 2026 | JP Morgan | Initiates | Overweight | $46 |
| 15 July 2026 | JP Morgan | Initiates | Overweight | — |
| 29 June 2026 | Canaccord Genuity | Maintains | Buy | $42 → $46 |
| 29 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 26 June 2026 | Jefferies | Upgrade | Buy | $27 → $60 |
| 26 June 2026 | Jefferies | Upgrade | Buy | — |
| 11 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 9 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 9 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 June 2026 | Leerink Partners | Maintains | Outperform | — |
| 15 May 2026 | Mizuho | Maintains | Outperform | — |
| 15 May 2026 | Piper Sandler | Downgrade | Neutral | — |
| 14 May 2026 | Jefferies | Downgrade | Hold | — |
| 14 May 2026 | Leerink Partners | Maintains | Outperform | — |
| 14 May 2026 | Wedbush | Maintains | Outperform | — |
| 27 Apr 2026 | Stifel | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TNGX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Tango Therapeutics, Inc. returned +247.7% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 5% of US stocks
Cheaper than 11% of US stocks
Cheaper than 90% of US stocks
Higher than 1% of US stocks
Higher than 10% of US stocks
Higher than 2% of US stocks
Higher than 31% of US stocks
Higher than 24% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Tango Therapeutics, Inc. has a market value of $4.0B and an enterprise value of $3.0B.
Revenue in the twelve months to 30 June 2026: $53.8M.
Net income over the same four quarters: −$123.7M, a −229.9% net margin.
Diluted earnings per share, trailing twelve months: $−0.85.
Free cash flow in the twelve months to 30 June 2026: −$144.3M.
Trailing P/E: −27.3×; forward P/E: −14.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Tango Therapeutics, Inc. employs 137 people — $393K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Tango Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Tango Therapeutics (TNGX) reported earnings 30 days ago, and its stock has since fallen 6.2%. The article examines what may come next for the company.
Why it matters — TNGX watchers would follow this update because it assesses the company's recent earnings report and its potential impact on the stock's direction.
On September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a new employee a non-qualified stock option to purchase 146,500 shares of common stock and 40,000 restricted stock units under the company's 2023 Inducement Plan. The grants were made effective September 1, 2026, and announced on September 3, 2026.
Why it matters — TNGX watchers would note this as a routine equity inducement grant that signals new-hire activity under the company's Nasdaq Listing Rule 5635(c)(4) inducement plan.
Tango Therapeutics announced that members of its management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.
Why it matters — TNGX watchers may be interested because the company's management will present at a major healthcare conference, offering potential exposure and visibility for the company.
Seeking Alpha reports that Tango Therapeutics' vopimetostat, combined with daraxonrasib, has produced an unusually strong early signal in pancreatic cancer, though from a very small, previously treated cohort. A planned front-line Phase 3 trial could expand the opportunity, but its design, timing, and regulatory path remain unsettled, with additional readouts needed across combinations, lung cancer, and CNS indications.
Why it matters — A TNGX watcher would care because the near-term value hinges on whether this early pancreatic signal develops into a larger, front-line opportunity and a broader PRMT5 franchise, or remains dependent on one limited dataset.
Tango Therapeutics shares fell 5% after reporting a wider-than-expected second-quarter loss, driven by higher operating expenses.
Why it matters — The stock decline reflects investor concern over rising costs, even as the company's pipeline progress continues to be a key area of focus.
The 12 Wall Street analysts covering Tango Therapeutics, Inc. have a median 12-month price target of $40, with estimates ranging from $24 to $69. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Tango Therapeutics, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tango Therapeutics, Inc. 41 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Tango Therapeutics, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +68.2% from the last close, and Ticker Nerd's factor model ranks Tango Therapeutics, Inc. 41 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Tango Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $69 over the next 12 months.
Tango Therapeutics, Inc. returned +247.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing precision cancer medicines for patients with significant unmet medical needs.
The most recent item we track (Zacks Investment Research, 10 Sept 2026): "Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?". Tango Therapeutics (TNGX) reported earnings 30 days ago, and its stock has since fallen 6.2%. The article examines what may come next for the company.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing precision cancer medicines for patients with significant unmet medical needs. The company applies synthetic lethality research to identify drug targets linked to specific genetic vulnerabilities in cancer cells, with an emphasis on tumor suppressor gene loss. Its current pipeline centers on precision oncology programs, including PRMT5 inhibitors and related targeted therapies designed for defined patient populations. Tango Therapeutics is developing treatments for hard-to-treat cancers such as pancreatic cancer, lung cancer, glioblastoma, and other genetically defined solid tumors. The company’s research and development activities position it within the oncology drug discovery segment, where targeted therapies play an important role in advancing more selective approaches to cancer treatment. Based in Boston, Massachusetts, Tango Therapeutics operates as a specialized biopharmaceutical company dedicated to translating genetic insights into new cancer medicines.
CEO Dr. Malte Peters M.D. · 137 employees · United States · https://www.tangotx.com
